Pfizer's Breakthrough Vaccine Findings

This chapter explores Pfizer and BioNTech's announcement of their COVID-19 vaccine candidate showing over 90% efficacy, alongside necessary cautions regarding sample size and lack of peer review. It covers the trial structure, the significance of mRNA technology, and the potential for emergency approval for high-risk individuals. Additionally, it addresses the large-scale challenges of global vaccination efforts, including manufacturing, distribution, and cold storage requirements.